EXEL
EXELIXIS, INC.
Biological Products, (No Diagnostic Substances)- 売上
- $2.3bn
- 時価総額
- $15.7bn
株価 $55.97 · 100株 5,597円
| 期 | 23/12 | 25/1変 | 26/01 |
|---|---|---|---|
| 売上 | $1.8bn | $2.2bn | $2.3bn |
| 成長率 | — | — | — |
| 総利益 | $1.8bn | $2.1bn | $2.2bn |
| 総利益率 | 96.0% | 96.5% | 96.4% |
| 販管費 | $543m | $492m | $519m |
| 販管費率 | 29.7% | 22.7% | 22.4% |
| 営利 | $171m | $605m | $872m |
| 営利率 | 9.3% | 27.9% | 37.6% |
| 純利益 | $208m | $521m | $783m |
| PBR | 6.9 | 7.0 | 7.2 |
| PSR | 8.6 | 7.2 | 6.8 |
| PGPR | 8.9 | 7.5 | 7.0 |
| PER | 75 | 30 | 20 |
| ﾈｯﾄｷｬｯｼｭ | $74m | $28m | $293m |
| EV/EBITDA | 79.3 | 24.7 | 17.1 |
| Rule of 40 | — | — | — |
| セールス効率 | — | — | — |
※Rule of 40は売上成長率＋営業利益率、セールス効率は売上総利益増加÷販管費増加（販管費増のときのみ）